




RealRate

PHARMACEUTICAL 2022

Dyne Therapeutics Inc.
Rank 225 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

Dyne Therapeutics Inc.
Rank 225 of 475

The relative strengths and weaknesses of Dyne Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dyne Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 139% points. The greatest weakness of Dyne Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is -83%, being 193% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	382,392
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,723
Liabilities, Non-Current	28,743
Other Assets	38,593
Other Compr. Net Income	-242
Other Expenses	0
Other Liabilities	0
Other Net Income	734
Property and Equipment	4,678
Research and Development	121,308
Revenues	0
Selling, General and Administrative Expense	28,717

Output Variable	Value in 1000 USD
Assets	425,663
Liabilities	57,466
Expenses	150,025
Stockholders Equity	368,197
Net Income	-149,291
Comprehensive Net Income	-149,412
Economic Capital Ratio	-83%

